Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.410
-0.020 (-1.40%)
At close: Nov 5, 2025, 4:00 PM EST
1.430
+0.020 (1.41%)
After-hours: Nov 5, 2025, 7:47 PM EST
Ocugen Revenue
Ocugen had revenue of $1.75M in the quarter ending September 30, 2025, with 54.23% growth. This brings the company's revenue in the last twelve months to $5.37M, up 14.26% year-over-year. In the year 2024, Ocugen had annual revenue of $4.05M, down -32.82%.
Revenue (ttm)
$5.37M
Revenue Growth
+14.26%
P/S Ratio
77.42
Revenue / Employee
$56,526
Employees
95
Market Cap
440.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.05M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OCGN News
- 11 hours ago - Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 hours ago - Ocugen Provides Business Update with Third Quarter 2025 Financial Results - GlobeNewsWire
- 13 days ago - Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Ocugen: A Retinal Disease Juggernaut In The Making - Seeking Alpha
- 7 weeks ago - Ocugen Shares Are Trading Higher Monday: What's Going On? - Benzinga
- 7 weeks ago - Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - GlobeNewsWire
- 2 months ago - Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 - GlobeNewsWire
- 3 months ago - Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - GlobeNewsWire